CAR-T

Transposons have the potential to make DNA editing easier, cheaper, and safer

Off-the-shelf allogeneic T-cell therapies have the potential to leverage the power of a healthy donor’s immune system

Challenges and critical considerations for the manufacturing of cellular therapies

The study suggests that increasing the protein's activity in T cells may enhance the effectiveness of immunotherapy

The engineered T cells can target and attack pathogenic T cells in a mouse model of Type 1 diabetes

The study is one of the first to demonstrate CAR T-cells achieving rapid regression against a solid cancer

Researchers from Penn, in collaboration with the Ragon Institute, develop a new dual CAR T cell immunotherapy that combats HIV infection in humanized mice

The largest report of commercial CAR T therapy for lymphoma demonstrates its effectiveness even in patients that would not have been eligible for clinical trials

A new study addresses a central conundrum of CAR-T therapies: their tendency to provoke potentially deadly runaway immune responses against healthy tissues in patients

Forty percent of patients with diffuse large B-cell lymphoma had a complete response, most of which were durable